Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL decreased its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 23.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 208,075 shares of the life sciences company's stock after selling 63,343 shares during the quarter. Tudor Investment Corp ET AL owned approximately 0.27% of Integra LifeSciences worth $4,719,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Quadrant Capital Group LLC increased its holdings in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 1,371 shares during the last quarter. Sterling Capital Management LLC grew its holdings in Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after acquiring an additional 2,800 shares during the last quarter. Covestor Ltd boosted its position in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after acquiring an additional 2,071 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Integra LifeSciences during the fourth quarter valued at $180,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on IART. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $22.71.

Integra LifeSciences Trading Down 21.2 %

Integra LifeSciences stock traded down $3.57 during trading hours on Monday, hitting $13.28. The company had a trading volume of 7,492,449 shares, compared to its average volume of 1,067,335. The company has a 50-day moving average price of $19.94 and a two-hundred day moving average price of $22.13. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 1 year low of $11.62 and a 1 year high of $32.66. The firm has a market cap of $1.03 billion, a P/E ratio of -147.54, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same period last year, the firm earned $0.55 EPS. The business's quarterly revenue was up 3.7% on a year-over-year basis. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.